Stockreport

Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF were close to $640 million in 2025, with Auvelity posting ~68% YoY growth and covered lives around The supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease ag [Read more]